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ABSTRACT
Introduction: The efficacy and safety of insulin
degludec/liraglutide (IDegLira) has been evalu-
ated in the Dual Action of Liraglutide and
Insulin Degludec in Type 2 Diabetes (DUAL)
phase 3 clinical trial program. In this post hoc
analysis, we compared the efficacy and safety of
IDegLira in the Indian subpopulation with the
results from the global trial population of DUAL
trials. The analysis includes participants
uncontrolled on oral antidiabetic drugs (OADs)
in DUAL I and DUAL IV and participants
uncontrolled on basal insulin and OADs in
DUAL II.
Methods: Three phase 3 trials were included in
the analysis: DUAL I extension (IDegLira vs.
insulin degludec or liraglutide 1.8 mg in par-
ticipants uncontrolled on metformin ± piogli-
tazone; 52 weeks; n = 1663), DUAL IV (IDegLira
vs. placebo as an add-on to a regimen of sul-
fonylurea ± metformin; 26 weeks; n = 435) and
DUAL II (IDegLira vs. insulin degludec in par-
ticipants uncontrolled on basal insulin ? OADs;
26 weeks; n = 398). There were 251, 64 and 64
participants, respectively, at the Indian sites.
Results: In the Indian subpopulations, the
reductions in glycated hemoglobin (HbA1c)
with IDegLira were substantial [DUAL I: 1.96%
(-21 mmol/mol); DUAL IV: -1.40% (-15
mmol/mol); DUAL II: -2.20% (-24 mmol/
mol)] and significantly greater than those in the
comparators in each trial. IDegLira was gener-
ally weight-neutral after the administration of
OADs (-0.3 and ?0.6 kg in DUAL I and DUAL
IV) and resulted in weight loss after the
administration of basal insulin (-2.1 kg in
DUAL II). Hypoglycemia rates were 1.98, 1.08
and 0.37 events/patient-years of exposure (PYE)
for IDegLira, insulin degludec and liraglutide in
DUAL I, 4.06 and 0.36 events/PYE for IDegLira
and placebo in DUAL IV and 1.16 and 0.83
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events/PYE with IDegLira and insulin degludec
in DUAL II.
Conclusions: Results from the Indian subpop-
ulations reflect those of the global study popu-
lations, supporting IDegLira as an effective and
safe treatment option for people with type 2
diabetes inadequately controlled on OADs or
basal insulin ? OADs in the South Asian
population.
Trial Registration: ClinicalTrials.gov identifier,
NCT01336023 (DUAL I), NCT01392573 (DUAL
II), NCT01618162 (DUAL IV).
Funding: Novo Nordisk A/S, Bagsvaerd,
Denmark.
Keywords: IDegLira; Indian population; Type 2
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INTRODUCTION
India has the second highest number of people
with diabetes worldwide, with approximately
8.6% of the population reported to have this
disease [1]. Glycemic control is poor in Indian
diabetic patients, with a mean glycated hemo-
globin (HbA1c) of 8.9 ± 2.1%
(74 ± 23 mmol/mol) and only 19.7% of the
Indian diabetic population achieving the
American Diabetes Association/European Asso-
ciation for the Study of Diabetes HbA1c target of
\7% (\53 mmol/mol) [2, 3]. In addition to the
increased prevalence of diabetes, higher rates of
diabetes-related complications and mortality
are also observed in South Asian people [4]. The
factors contributing to this situation are multi-
factorial and include a genetic predisposition to
diabetes, increased visceral adiposity and insu-
lin resistance in this population, which are
compounded by lifestyle factors [5]. Despite
these numbers, South Asian participants in tri-
als of glucose-lowering therapies are under-rep-
resented [6]; hence, it is important to report trial
data from diverse populations.
IDegLira is a novel, once-daily, titratable,
fixed-ratio combination of insulin degludec
(IDeg) and the glucagon-like peptide-1 receptor
agonist (GLP-1RA) liraglutide (Lira) that has
been developed for the treatment of people
with type 2 diabetes [7–9]. Importantly,
GLP-1RAs act in a glucose-dependent manner
and are also commonly associated with a low
risk of hypoglycemia and weight loss [10]. The
efficacy and safety of IDegLira and the benefits
of its complementary mode of action have been
examined in the large global DUAL clinical trial
program [7–9, 11]. Here we describe a post hoc
analysis of the efficacy and safety of IDegLira in
participants from Indian trial sites included in
the DUAL program. Our hypothesis was that the
safety and efficacy of IDegLira in the Indian
subpopulation would be similar to that
demonstrated for the global population.
METHODS
This post hoc analysis used data from the IDe-
gLira (Novo Nordisk, Bagsværd, Denmark)
phase 3 trials which included participants with
type 2 diabetes from Indian trial sites, namely,
the DUAL I extension (52 weeks of data), DUAL
IV and DUAL II trials, which included Indian
sites [8, 9, 11].
Study Designs
The study designs of DUAL I extension, DUAL
II and DUAL IV have been described previously
[8, 9, 11] and include participants uncontrolled
on oral antidiabetic drugs (OADs; DUAL I
extension and DUAL IV) and participants
uncontrolled on basal insulin ? OADs (DUAL
II). The aim of DUAL I extension was to
investigate the efficacy and safety of IDegLira
versus its individual components IDeg or Lira
alone in participants inadequately controlled
by metformin ± pioglitazone over 52 weeks [8].
In DUAL IV IDegLira was compared with pla-
cebo, both added on to a therapeutic regimen
of sulphonylurea ± metformin [9], and in
DUAL II, IDegLira was compared to IDeg
(maximum dose of 50 U) in participants inad-
equately controlled on 20–40 U of basal insulin
? one to two OADs [11]. Owing to differences
in trial design, individual trial data were ana-
lyzed separately, rather than pooling the IDe-
gLira data.
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Endpoints and Statistical Analyses
The primary endpoint in each study was change
from baseline in HbA1c. Secondary efficacy
endpoints included participants achieving a
HbA1c of\7% (\53 mmol/mol), change in body
weight, insulin dose and laboratory-measured
fasting plasma glucose (FPG). Safety endpoints
included adverse events (AEs) and confirmed
hypoglycemia [severe (unable to self-treat) and/
or plasma glucose level of \3.1 1 mmol/L].
Change from baseline in HbA1c, FPG and body
weight were analyzed using an analysis of
covariance (ANCOVA) model with treatment
and pre-trial medication as fixed factors, and
baseline HbA1c stratum (DUAL I only), sub-
study (DUAL I only) and baseline value as
covariates—all performed on the full analysis
set using last observation carried forward
(LOCF) method to impute missing values.
Attainment of a HbA1c level of \7% was ana-
lyzed using a logistic regression model (with
LOCF), with the same explanatory variables as
used for the primary endpoint. The results of
the analyses were also summarized descriptively
for other endpoints (insulin dose, rates of
hypoglycemia and other safety endpoints).
As a post hoc analysis, the original individual
trials were not powered to perform statistical
analyses in the Indian subpopulations. The
study reported here is based on a post hoc
analysis of previously conducted studies and
does not involve any new studies of human or
animal subjects performed by any of the
authors.
RESULTS
The Indian subpopulations comprised 15, 16
and 15% of the global trial populations of the
DUAL I extension, DUAL II and DUAL IV trials,
corresponding to 251, 64 and 64 participants,
respectively. Baseline characteristics of the glo-
bal trial populations and Indian subpopulations
are shown in Table 1. Overall, the baseline
characteristics of the Indian subpopulations
were largely comparable to those of the global
trial populations, although the Indian
participants had lower FPG and body mass
index (BMI).
Glucose Control
The change in HbA1c from baseline and
end-of-trial HbA1c in the global study popula-
tions and the Indian subpopulations from the
three studies are shown by patient population
in Fig. 1. Considering patients previously
uncontrolled on OAD(s), in the Indian sub-
population of DUAL I extension, IDegLira
resulted in a statistically significantly greater
HbA1c reduction versus IDeg [estimated treat-
ment difference (ETD) -0.91%; 95% confidence
interval (CI) -1.21 to -0.61 (-10 mmol/mol;
95% CI -13 to -7); p\0.0001] and versus Lira
[ETD -0.77%; 95% CI -1.08 to -0.46
(-8 mmol/mol; 95% CI -12 to -5); p\0.0001].
In DUAL IV, a significantly greater reduction
was observed with IDegLira versus placebo
[ETD: -0.78%; 95% CI -1.25 to -0.31
(-9 mmol/mol; 95% CI -14 to -3); p = 0.002]
in the Indian subpopulation. In patients previ-
ously uncontrolled on basal insulin (DUAL II),
IDegLira also resulted in a greater HbA1c reduc-
tion versus IDeg [maximum dose 50 U; ETD
-1.32%; 95% CI -1.80 to -0.85
(-14 mmol/mol; 95% CI -20 to -9);
p\0.0001] in the Indian subpopulation.
The proportion of participants in the global
study populations and the Indian subpopula-
tions achieving HbA1c\7% (\53 mmol/mol) are
shown in Fig. 2. In the Indian subpopulation of
the DUAL I extension trial, participants were
significantly more likely to achieve an HbA1c of
\7% (\53 mmol/mol) with IDegLira than with
IDeg [84.0 vs. 43.1%; odds ratio (OR) 6.77; 95%
CI 3.35–13.65; p\0.0001] or with Lira (84.0 vs.
47.5%; OR 5.84; 95% CI 2.86–11.90;
p\0.0001). Participants were also more likely
to achieve an HbA1c of \7% (\53 mmol/mol)
with IDegLira than with placebo in the DUAL IV
trial (69.6 vs. 16.7%; OR 11.47; 95% CI
2.79–47.17; p\0.001). In DUAL II, participants
were also more likely to achieve an HbA1c of
\7% (53 mmol/mol) with IDegLira versus IDeg











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In the DUAL I extension trial, IDegLira
resulted in a greater FPG reduction versus Lira
(ETD -29.80 mg/dL; 95% CI -39.62 to -19.98;
p\0.0001); differences versus IDeg were not
statistically significant [TD -7.04 mg/dL; 95%
CI -16.57 to 2.50; p = not significant (ns)].
Differences versus placebo in the DUAL IV trial
were also not statistically significant (ETD
-18.65 mg/dL; 95% CI -38.80 to 1.50; p = ns).
IDegLira resulted in a greater FPG reduction
versus IDeg (maximum dose 50 U) in DUAL II
(ETD -34.26 mg/dL; 95% CI -53.28 to -15.24;
p = 0.0006).
Body Weight
In the Indian subpopulation of the DUAL I
extension trial, IDegLira was weight neutral
(-0.3 kg), whereas body weight increased with
IDeg (1.8 kg; ETD -1.61 kg; 95% CI -2.45 to
-0.78; p = 0.0002) and decreased with Lira
Fig. 1 Mean change in glycated hemoglobin (HbA1c) and
end-of-trial HbA1c in the global study population and the
Indian subpopulations of the DUAL I extension, DUAL
IV and DUAL II trials (maximum 50 U) [8, 9, 11, 12].
Mean observed values are based on full analysis set and
data inputted using the last observation carried forward
(LOCF) method. Treatment difference is estimated from
an analysis of covariance (ANCOVA) analysis. CI Con-
ﬁdence interval EOT end of trial, ETD estimated
treatment difference, IDeg insulin degludec, IDegLira
insulin degludec/liraglutide, Lira liraglutide, OAD oral
antidiabetic drug
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(-2.3 kg; ETD 1.72 kg; 95% CI 0.87–2.58;
p\0.0001) (Fig. 3). In DUAL IV, the mean
weight change was 0.6 kg with IDegLira and
-0.9 kg with placebo (ETD 1.37 kg; 95% CI
0.31–2.43; p = 0.0124). IDegLira resulted in a
greater weight loss versus IDeg (ETD -1.91 kg;
95% CI -3.39 to -0.43; p = 0.01223) in DUAL
II. Across the studies, baseline body weights
were lower in the Indian subpopulations.
Insulin Dose
End-of-trial insulin dose was 35 U with IDegLira
and 59 U with IDeg in the DUAL I extension
trial, 25 U with IDegLira in the DUAL IV trial
and 42 and 46 U with IDegLira and IDeg in the
DUAL II trial.
Safety Endpoints
Adverse events for the global populations and
Indian subpopulations are summarized in
Table 2. Rates of gastrointestinal AEs (combined
diarrhea, nausea and vomiting) were 25.3
events per 100 patient-years of exposure (PYE)
in the IDegLira group, 8.5 per 100 PYE in the
IDeg group and 75.3 per 100 PYE in the Lira-
treated group in the DUAL I extension trial, and
Fig. 2 Percentages of participants achieving the HbA1c
target of \7% in the global study population and the
Indian subpopulations of the DUAL I extension, DUAL
IV and DUAL II trials (maximum 50 U) [8, 9, 11, 12].
Mean observed values are based on the full analysis set and
LOCF inputted data. The odds ratio (OR) is estimated
from a logistic regression analysis
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9.4 (IDegLira) and 36.2 (placebo) events/100
PYE in DUAL IV. In DUAL II, the rates were 82.1
(IDegLira) and 20.7 (IDeg) events/100 PYE.
There were no severe hypoglycemic epi-
sodes in the Indian subpopulations of the
three trials. Confirmed hypoglycemia rates
were 1.98, 1.08 and 0.37 events/PYE in the
IDegLira, IDeg and Lira groups, respectively,
in the DUAL I extension trial (compared with
1.77, 2.79 and 0.19 events/PYE in the global
trial population) and 4.06 and 0.36 events/
PYE with IDegLira and placebo, respectively,
in DUAL IV (compared with 3.52 and 1.35
events/PYE in the global trial population). In
DUAL II, confirmed hypoglycemia rates were
1.16 and 0.83 events/PYE with IDegLira and
IDeg, respectively (compared with 1.53 and
2.63 events/PYE in the global trial
population).
DISCUSSION
In the Indian subpopulations, IDegLira resulted
in substantial HbA1c reductions that were sig-
nificantly greater than those achieved by all
comparators. Mean end-of-trial HbA1c with
IDegLira was\7% (\53 mmol/mol) in all trials
and more participants achieved a HbA1c target
of\7% (\53 mmol/mol) versus all comparators,
consistent with the global trial populations
[8, 9, 11].
Fig. 3 Mean change in body weight in the global study
population and Indian subpopulations of the DUAL I
extension, DUAL II and DUAL IV trials [8, 9, 11].
Maximum dose of IDeg was 50 U in DUAL II. Mean
observed values are based on full analysis set and LOCF
inputted data. Treatment difference is estimated from an
ANCOVA analysis
Diabetes Ther
IDegLira was generally weight-neutral when
used as an add-on to oral therapy (DUAL I
extension/DUAL IV) and resulted in weight loss
when used after basal insulin (DUAL II).
Considering IDegLira alone, rates of con-
firmed hypoglycemia were consistent with
those observed with IDegLira in the global trial
populations. However, the rate of confirmed
hypoglycemia with IDeg was substantially lower
in the Indian subpopulations (by around 1.7/
1.8 events/PYE) versus the global trial popula-
tions of DUAL I and II. As a result, the rate of
confirmed hypoglycemia was numerically lower
with IDeg versus IDegLira in the Indian sub-
populations of DUAL I and II, while in the
global trial population IDegLira resulted in a
lower rate of hypoglycemia versus IDeg, reach-
ing statistical significance in the DUAL I trial
[8, 9]. This difference might be explained by the
small number of participants—and therefore
hypoglycemic events—in the Indian
subpopulations and by baseline differences. The
hypoglycemia rates should also be considered in
the context of the significantly lower mean
end-of-trial HbA1c achieved with IDegLira
compared to comparators.
IDegLira was generally well tolerated, with a
lower rate of gastrointestinal AEs in the Indian
subpopulation versus the global trial popula-
tions in DUAL I and IV, and a higher rate in
DUAL II. Across all trials, the proportion of
participants experiencing AEs was higher in the
Indian subpopulation than in the global trial
population, but the pattern of AEs did not differ
[8, 9, 11].
An inherent limitation of this study is that it
is a post hoc analysis of three randomized con-
trolled DUAL trials that were not designed to
compare the safety and efficacy of IDegLira in
the Indian subpopulation versus the global
population. As such, there were differences at
baseline in terms of FPG and BMI with the
Table 2 Adverse events reported in the DUAL I extension, DUAL II and DUAL IV trials (full analysis set)
Adverse events Uncontrolled on OAD(s) Uncontrolled on basal
insulin
DUAL I extension DUAL IV DUAL II
IDegLira IDeg Lira IDegLira Placebo IDegLira IDeg
Global trial population
Number of exposed participants 825 412 412 288 146 199 199
Percentage of participants with AEs 71.2 70.6 77.2 N/Aa N/Aa 57.8 61.3
AE rate per 100 PYE 407.9 383.3 507.3 401.4 367.0 398.1 355.5
Percentage of participants with SAEs 4.6 5.3 5.8 N/Aa N/Aa 3.5 5.5
SAE rate per 100 PYE 6.7 8.9 9.3 20.3 8.0 12.0 14.4
Indian subpopulation
Number of exposed participants 125 65 60 45 18 32 32
Percentage of participants with AEs 76.8 76.9 93.3 80.0 61.1 81.3 87.5
AE rate per 100 PYE 364.1 332.1 543.3 363.4 349.5 766.5 577.0
Percentage of participants with SAEs 2.4 1.5 5.0 0.0 0.0 3.1 3.1
SAE rate per 100 PYE 3.6 1.7 6.8 0.0 0.0 6.8 13.8
See Gough et al. [8], Rodbard et al. [9] and Buse et al. [11] for more detail on these trials
Data are based on safety analysis set
AEs Adverse events, N/A not available, PYE patient-years of exposure, SAEs serious adverse events
a Data for percentage of participants with AEs in the entire trial population for DUAL IV have not been published to date
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Indian subpopulation compared with the global
population. Furthermore, owing to trial design
differences, individual trial data were analyzed
separately rather than the IDegLira data being
pooled, and therefore sample sizes were small.
Differences between Indian and non-Indian
populations were not analyzed as the Indian
population constituted a relatively low propor-
tion of the global population.
CONCLUSION
In conclusion, results from the Indian subpop-
ulations largely reflected those of the global
study populations. These results provide evi-
dence to support the efficacy and safety of
IDegLira as a treatment modality for partici-
pants with type 2 diabetes uncontrolled on
OADs and/or basal insulin of the South Asian
population, offering better glucose control than
either component alone, improved weight pro-
file versus the basal insulin component, and
with fewer gastrointestinal side effects than a
GLP-1 analogue.
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